Animals, Anti-Bacterial Agents, Biofilms, Catheter-Related Infections, Cytokines, Disease Models, Animal, Humans, Methicillin-Resistant Staphylococcus aureus, Microbial Sensitivity Tests, Peptides, Peptides, Cyclic, Rats, Rats, Sprague-Dawley, Staphylococcal Infections, Vancomycin
This work was supported by grants from the Irish Health Research Board (HRA-POR-2012–52 to E. O’N., H. H. and J. P. O’G.) and the Healthcare Infection Society (to E. O’N.). The authors are grateful to Science Foundation Ireland for supporting the study with an equipment grant (06/RFP/CHO024/EC07).
Here, we demonstrate that antimicrobial peptides (AMPs) are an effective antibiofilm treatment when applied as catheter lock solutions (CLSs) against S. aureus biofilm infections. The activity of synthetic AMPs (Bac8c, HB43, P18, Omiganan, WMR, Ranalexin, and Polyphemusin) was measured against early and mature biofilms produced by methicillin-resistant S. aureus and methicillin-susceptible S. aureus isolates from patients with device-related infections grown under in vivo-relevant biofilm conditions. The cytotoxic and hemolytic activities of the AMPs against human cells and their immunomodulatory potential in human blood were also characterized. The D-Bac8c2,5Leu variant emerged as the most effective AMP during in vitro studies and was also highly effective in eradicating S. aureus biofilm infection when used in a CLS rat central venous catheter infection model. These data support the potential use of D-Bac8c2,5Leu, alone or in combination with other AMPs, in the treatment of S. aureus intravenous catheter infections.
Medicine and Health Sciences
Zapotoczna M, Forde É, Hogan S, Humphreys H, O'Gara JP, Fitzgerald-Hughes D, Devocelle M, O'Neill E. Eradication of Staphylococcus aureus Biofilm Infections Using Synthetic Antimicrobial Peptides. Journal of Infectious Diseases. 2017;215(6):975-983.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.